Pleuropulmonary disease associated with dopamine agonist therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 1686385.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Artificial dopamine agonists are widely employed for the treatment of idiopathic parkinsonism. Pleuropulmonary disease has previously been reported to occur with the use of bromocriptine and mesulergine. We report similar adverse effects induced by the newer agonists lisuride and cabergoline. All these agents are tetracyclic ergot derivatives. This suggests a causal link between ergot-derived dopamine agonists and pleuropulmonary disease.
Medical subject headings
- Dopamine Agents
- Lung Diseases
- Pleural Diseases